Real-World Data (RWD) Capabilities: Benchmarking Pharma Companies (2019) - Includes 60 Insights Supported by 136 Directly Quoted Comments from Industry Experts
DUBLIN, Dec. 17, 2019 /PRNewswire/ -- The "Real-World Data Capabilities: Benchmarking Pharma Companies (2019)" report has been added to ResearchAndMarkets.com's offering.
https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
Are you fully and efficiently exploiting real-world data across your business?
The impact of real-world data (RWD) is growing but few companies are fully exploiting its potential across all clinical and commercial areas. While most companies are focusing their RWD efforts towards meeting the evidence requirements of payers, RWD is also being used to define clinical research and optimize market access and commercialization strategies.
As advancing digital technologies open new ways to integrate and interrogate structured and unstructured data, pharma must continue to invest in their RWD capabilities and overcome the internal and external barriers to progress.
In Real-World Data Capabilities: Benchmarking Pharma Companies (2019), experienced RWD executives from leading companies such as Pfizer, Sanofi, J&J, and Teva assess current RWD applications and identify the data collection, technology and evaluation capabilities that are essential to realizing the full value of RWD.
RWD experts tackle key questions:
-- How are RWD capabilities being leveraged to meet the demands of
value-based healthcare?
-- Drug development? Clinical trial design? Patient experience management?
Where are RWD capabilities being applied?
-- What technological upgrades and data science capabilities have been
invested in to gain RWD competence and what analytical skills do
companies need to develop?
-- What internal and external talents and expertise are required to
optimize RWD capabilities and can they be acquired?
-- What are the necessary changes to cross-functional
communication/collaboration within organizations to ensure the
successful adoption of RWD capabilities?
Case studies included:
-- Novartis center of excellence for RWE
-- Sanofi invests in the Darwin platform
-- Pfizer and Concerto HealthAI for RWE generation
-- The OHDSI project
-- IMI Harmony's pre-competitive collaboration
What to expect:
-- A detailed report revealing the insights of pharma industry experts for
building and exploiting RWD capabilities across a company's organization
-- An examination of 8 key issues drug developers need to understand to
fully optimize RWD
-- 17 targeted questions put to industry experts
-- Their perceptive responses that provide 60 insights supported by 136
directly quoted comments
Companies Mentioned
-- Concerto HealthAI
-- IMI Harmony
-- J&J
-- Pfizer
-- Sanofi
-- Teva
For more information about this report visit https://www.researchandmarkets.com/r/4yef6s
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
